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OBJECTIVE — To investigate whether insulin reduces the magnitude of oxidative, nitrosa-
tive, and inﬂammatory stress and tissue damage responses induced by endotoxin (lipopolysac-
charide [LPS]).
RESEARCH DESIGN AND METHODS — Nine normal subjects were injected intrave-
nously with 2 ng/kg LPS prepared from Escherichia coli. Ten others were infused with insulin (2
units/h) for6hi naddition to the LPS injection along with 100 ml/h of 5% dextrose to maintain
normoglycemia.
RESULTS — LPS injection induced a rapid increase in plasma concentrations of nitric oxide
metabolites,nitriteandnitrate(NOM),andthiobarbituricacid–reactingsubstances(TBARS),an
increase in reactive oxygen species (ROS) generation by polymorphonuclear leukocytes
(PMNLs), and marked increases in plasma free fatty acids, tumor necrosis factor- (TNF-),
interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), macrophage migration in-
hibition factor (MIF), C-reactive protein, resistin, visfatin, lipopolysaccharide binding protein
(LBP), high mobility group-B1 (HMG-B1), and myoglobin concentrations. The coinfusion of
insulin led to a total elimination of the increase in NOM, free fatty acids, and TBARS and a
signiﬁcant reduction in ROS generation by PMNLs and plasma MIF, visfatin, and myoglobin
concentrations.InsulindidnotaffectTNF-,MCP-1,IL-6,LBP,resistin,andHMG-B1increases
induced by the LPS.
CONCLUSIONS — Insulin reduces signiﬁcantly several key mediators of oxidative, nitro-
sative, and inﬂammatory stress and tissue damage induced by LPS. These effects of insulin
require further investigation for its potential use as anti-inﬂammatory therapy for endotoxemia.
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E
ndotoxin (lipopolysaccharide [LPS])
induces inﬂammation by binding to
its speciﬁc receptor, Toll-like recep-
tor-4 (TLR-4) (1,2). This leads to the nu-
clear translocation and activation of
nuclear factor B (NFB), the major
proinﬂammatory transcription factor,
and an increase in the transcription of
proinﬂammatory genes with a corre-
sponding increase in the concentration of
theproductsofthesegenesinplasma.En-
dotoxemia in association with clinical
Gram-negative septicemia syndrome in
humans leads to a high incidence of mor-
bidityandmortality,especiallyinpatients
in intensive care units (ICUs).
Insulin has been shown to suppress
inﬂammatory changes in vitro and in
vivo.ItsuppressesintranuclearNFBand
Egr-1 binding and the expression of sev-
eral proinﬂammatory mediators includ-
ingintercellularadhesionmolecule-1and
monocyte chemoattractant protein-1
(MCP-1), matrix metalloproteinase-9, C-
reactive protein (CRP), and serum amy-
loid A (3,4). In addition, it suppresses the
expression of several Toll-like receptors
(TLRs) (5). It also suppresses reactive ox-
ygen species (ROS) generation and
p47
phox expression.
Resistin and visfatin, two peptides
originally discovered as adipokines (6,7),
have now been shown to be products of
proinﬂammatory myeloid cells (8,9) and
to induce proinﬂammatory cytokines,
chemokines, and ROS. Both have been
implicated in atherogenesis (10).
LPSinducesanincreaseintheexpres-
sion of inducible nitric oxide synthase
and NO release (11) from macrophages.
LPS is also known to stimulate the gener-
ation of ROS including superoxide.
There are recent data showing that
LPS injection in experimental animals
leads to a reduction in myocardial func-
tion. Insulin administration in LPS-
injected animals reduces LPS-induced
damage (12).
Onthebasisoftheabove,wehypoth-
esized that 1) the injection of LPS in nor-
mal human subjects will induce an
increase in ROS generation, lipid peroxi-
dation, nitrosative stress as reﬂected in
plasma concentrations of NO metabo-
lites, nitrite and nitrate, plasma free fatty
acid concentration, plasma myoglobin
concentrations.noveladipokines,resistin
and visfatin, and lipopolysaccharide
binding protein (LBP) in parallel with
proinﬂammatorycytokinessuchastumor
necrosis factor- (TNF-), interleukin-6
(IL-6), and macrophage migration inhib-
itory factor (MIF), and high mobility
group box-1 (HMG-B1) protein, which
acts as a proinﬂammatory cytokine when
releasedintothecirculationand2)insulin
will suppress the LPS-induced increases
in ROS generation, lipid peroxidation,
plasma concentrations of nitrite and ni-
trate (NOM), free fatty acids (FFAs), re-
sistin, visfatin, and markers of tissue
damage including myoglobin, HMG-B1,
TNF-, and IL-6.
RESEARCH DESIGN AND
METHODS— Nineteen normal-
weight (BMI 20–25 kg/m
2) healthy male
subjects aged between 20 and 33 years
(mean age 26  3 years) were recruited
forthisstudy.Afteranovernightfast,nine
subjects were injected intravenously with
2 ng/kg of LPS prepared from Escherichia
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other 10 were infused with insulin (2
units/h)1hbeforetheLPSinjectionalong
with 100 ml/h of 5% dextrose coinfused
with insulin to maintain normoglycemia.
Insulin/dextrose or saline infusions were
continued for 6 h after the LPS injection
while subjects were in the fasting state to
avoid the potential proinﬂammatory ef-
fect of a meal (13). They were then pro-
vided with a 900-calorie meal at 6:00 P.M.
after which they ate nothing till the next
morning. Subjects were monitored for vi-
tal signs (temperature, pulse, blood pres-
sure, headaches, body aches, and chills)
for 24 h after the LPS injection. Blood
samples were collected 1 h before the LPS
injectionandat0,1,2,4,6,and24hafter
the injection. The protocol was approved
by the internal review board of the State
University of New York at Buffalo, and
written consent was obtained from all
subjects.
Polymorphonuclear leukocytes
isolation and ROS generation
Blood samples were collected and poly-
morphonuclear leukocytes (PMNLs)
were isolated and ROS generation was
measured as described previously (14).
The intra-assay coefﬁcient of variation
(CV) for ROS generation is 8%.
Measurement of glucose, insulin,
FFAs, NOM, and thiobarbituric
acid–reacting substance
concentrations and homeostasis
model assessment of insulin
resistance calculation
Plasma concentrations of glucose were
measured by a 2300 STAT Plus glucose
analyzer (YSI, Yellow Springs, OH). Insu-
lin concentrations were measured from
plasma samples using an ELISA kit (Diag-
nostics Systems Laboratories, Webster,
TX). FFA concentrations were measured
usingtheHalf-Microcalorimetrickitfrom
Roche Diagnostic (Indianapolis, IN).
NOM (NO2/NO3) were assayed by the
Griess reaction (R&D Systems, Minneap-
olis, MN), and thiobarbituric acid–
reacting substances (TBARS) were
assayed by spectroﬂuorometry with a kit
from Zeptometrix (Buffalo, NY). The CVs
for these assays ranged from 2 to 7 and 4
to 11% for intra- and interassay varia-
tions, respectively. Homeostasis model
assessment of insulin resistance (HOMA-
IR) was calculated according to the for-
mula: (fasting insulin [microunits per
milliliter)  fasting glucose [millimoles
per liter])/22.5.
Measurements of plasma cytokines,
CRP, visfatin, resistin, myoglobin,
HMG-B1, and LBP concentrations
CommerciallyavailableELISAswereused
to measure concentrations of circulating
cytokine concentrations (R&D Systems),
CRP (American Diagnostica, Stamford,
CT), visfatin (Phoenix Pharmaceuticals,
Belmont, CA), myoglobin (Life Diagnos-
tics, West Chester, PA), HMG-B1 (IBL
Transatlantic), and LBP (Cell Sciences,
Canton, MA). The CVs for these assays
rangedfrom3to8and6to11%forinter-
and intra-assay variations, respectively.
Statistical analysis
Statistical analysis was conducted using
SigmaStat software (SPSS, Chicago, IL).
All data are means  SEM. Statistical anal-
ysis from baselines was preformed using
Holm-Sidak one-way repeated-measures
analysis of variance (RMANOVA). Dun-
nett’s two-factor RMANOVA method was
usedformultiplecomparisonsbetweendif-
ferent groups. Paired t tests were used to
compare changes from baseline at 24 h.
RESULTS
Clinical features
LPS injection induced an increase in tem-
perature from 97.7  0.5°F to a peak of
100.9  0.9°F at 4 h, systolic blood pres-
sure increased from 113  11 mmHg to a
peakof12913mmHgat2h,andpulse
rate increased from 63  7/min to a peak
of 97  9/min at 6 h and was not affected
by insulin (Table 1). Headaches, chills,
and body ache scores increased after LPS
injection with peaks at 1 to 2 h with insu-
lin infusion reducing body ache score sig-
niﬁcantly (Table 1) without affecting
headaches and chills.
Blood leukocyte counts
AfterLPS,totalleukocytecountincreased
fromabaselineof4,300900at1hto
apeakof11,8001,200cells/mm
3at6h
and was still elevated (7,000  1,100
cells/mm
3) at 24 h, mainly attributable to
polymorphonuclear leukocytosis (Table
1). Monocytes and lymphocytes fell rap-
idlyfrom60.4to0.50.1%andfrom
39  5t o3 0.8%, respectively. Insulin
infusion did not alter this pattern. The
marked reduction in monocytes and lym-
phocytes prevented us from examining
ROS generation and other cellular mark-
ers/mediators in the mononuclear cell
fraction.
Plasma insulin, glucose, FFA,
triglyceride, LDL cholesterol, and
HDL cholesterol concentrations
In the group receiving insulin, insulin
concentrations increased by up to four-
fold (P  0.001) (Table 1). In the control
group, insulin concentrations did not
change in the ﬁrst 6 h but were signiﬁ-
cantly higher than baseline at 24 h (P 
0.05) (Table 1). There was no signiﬁcant
change in glucose concentrations. Con-
sistent with that ﬁnding, HOMA-IR in-
creased signiﬁcantly at 24 h from 1.22 
0.24 vs. 2.36  0.39 in the control group
(Table 1). After LPS injection, there was a
signiﬁcant increase in plasma FFA con-
centration. Insulin infusion prevented
thisincrease(Table1).Serumtriglyceride
concentration fell signiﬁcantly in both
groups (Table 1). LDL cholesterol, VLDL
cholesterol, and HDL cholesterol concen-
trations did not change.
ROS generation by PMNLs
LPS injection induced an increase in ROS
generation by PMNLs of 200  42% over
the basal with a peak at 1 h and another
peak at 4–6 h. Insulin infusion reduced
(Fig. 1A) ROS generation throughout the
infusion period (P  0.05 by two-factor
RMANOVA).
Plasma TBARS concentrations
LPS injection induced a rapid increase in
TBARS concentration from 1.29  0.29
to 2.15  0.41 mol/l (P  0.01) at 1 h,
with a return to baseline at 2 h (Fig. 1B).
This pattern was observed in each of the
LPS-injectedsubjects.Insulininfusionto-
tally prevented this increase.
Plasma NOM concentrations
Plasma NOM concentration increased
rapidly after the injection of LPS at 1 h,
peaked to 75  24% over the baseline at
2h(from29.42.6to47.75.4mol/
l), and declined to the baseline by 4 h.
There was a secondary rise in NOM con-
centration at 6 h (Fig. 1C). With insulin
infusion, the LPS-induced increase in
NOM was totally prevented and in fact
there was a small but signiﬁcant decrease
by 16  10% below the baseline in
plasma NOM concentrations (from
31.7  2.8 to 26.9  2.6 mol/l).
Plasma MIF, TNF-, IL-6, and CRP
concentrations
Plasma concentrations of MIF increased
signiﬁcantlyafterLPSinjectionat1hwith
asecondaryincreaseat4–6hfrom727
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 11, NOVEMBER 2010 2417Table 1—Changes in clinical, oxidative, and inﬂammatory end points after 2 ng/kg injection of LPS alone or LPS and 2 units/h insulin for 6 h
in normal healthy subjects
Marker and group 1h 0h 1h 2h 4h 6h 2 4h P value* P value†
Systolic blood pressure
(mmHg)
LPS 113  11 111  10 118  12 129  13 123  12 118  10 118  12 0.01 NS
LPS 119  11 117  10 120  12 135  14 124  13 119  10 119  11 0.01
Diastolic blood pressure
(mmHg)
LPS  Ins 74  77 3  77 4  87 4  10 75  10 74  67 6  7N SN S
LPS  Ins 75  97 4  87 6  97 7  10 76  10 75  97 6  8N S
Temperature (°F)
LPS 97.7  0.5 97.5  0.5 98.0  0.7 98.4  0.5 100.9  0.9 99.1  0.9 97.5  0.5 0.001 NS
LPS  Ins 97.8  0.7 97.8  0.6 98.2  0.7 98.6  0.7 101.1  1.0 99.3  0.9 97.5  0.6 0.001
White blood cell count
(10
3 cells/mm
3)
LPS 4.3  0.8 4.1  0.7 2.8  0.5 6.8  0.9 10.4  1.1 11.8  1.2 7.0  1.1 0.001 NS
LPS  Ins 4.8  0.9 4.6  0.8 3.4  0.6 6.1  0.8 9.8  1.1 10.6  1.0 6.8  0.9 0.001
Pulse (/min)
LPS 63  76 0  76 3  77 6  88 8  99 7  96 4  6 0.001 NS
LPS  Ins 65  86 3  66 6  58 1  79 1  89 6  96 2  6 0.001
Body aches score
LPS 0.0 0.0 0.47  0.2 1.22  0.3 0.76  0.3 0.34  0.1 0.0 0.001 0.02
LPS  Ins 0.0 0.0 0.61  0.2 0.88  0.3 0.32  0.1 0.25  0.1 0.0 0.01
Glucose (mg/dl)
LPS 87.2  2.6 89.9  2.4 88.6  4.5 85.5  4.9 84.5  4.2 84.5  3.3 86.6  3.0 NS NS
LPS  Ins 83.6  2.0 85.7  2.2 81.4  5.3 82.9  3.2 87.3  4.5 80.2  4.8 85.6  2.5 NS
Insulin (IU/ml)
LPS 6.9  1.8 6.4  1.4 7.4  1.6 7.2  1.2 6.4  1.1 5.9  1.1 13.1  2.2‡ NS 0.001
LPS  Ins 7.5  1.5 31.1  3.7 30.5  5.1 24.9  4.2 15.4  2.8 28.9  4.8 14.9  3.0‡ 0.004
HOMA-IR
LPS 1.22  0.24 2.36  0.39‡
LPS  Ins 1.33  0.28 2.48  0.41‡
FFA (mmol/l)
LPS 0.39  0.08 0.35  0.05 0.28  0.04 0.51  0.09 0.62  0.1 0.82  0.12 0.32  0.09 0.012 0.024
LPS  Ins 0.29  0.07 0.29  0.08 0.11  0.02 0.16  0.06 0.32  0.08 0.36  0.08 0.31  0.07 0.005
Triglyceride (mg/dl)
LPS 141  24 140  24 132  23 133  21 108  20 92  18 94  18 0.02 NS
LPS  Ins 125  21 118  19 109  23 104  19 106  22 83  17 89  17 0.01
CRP (mg/l)
LPS 1.16  0.34 1.13  0.28 1.21  0.23 1.13  0.21 1.46  0.36 3.07  0.52 15.03  1.1 0.001 NS
LPS  Ins 1.27  0.37 1.27  0.39 1.28  0.29 1.21  0.34 1.56  0.35 3.39  0.61 14.25  1.3 0.001
TNF- (pg/ml)
LPS 1.2  0.7 1.2  0.7 123  29 136  40 18  6 8.3  2.2 2.6  1.1 0.002 NS
LPS  Ins 0.9  0.6 0.9  0.6 138  34 134  43 21  8 8.1  2.1 2.1  0.8 0.001
IL-6 (pg/ml)
LPS 2.49  0.8 2.49  0.8 25.7  8 48.9  4.5 48.3  6.1 22.8  5.3 4.8  1.1 0.002 NS
LPS  Ins 1.9  0.8 1.9  0.8 26.9  7 50.7  4.3 49.2  1.8 24.3  4.3 4.4  2.8 0.003
MCP-1 (ng/ml)
LPS 727  111 727  111 1,056  133 1,003  117 1,081  140 1,345  145 828  138 0.008 0.028
LPS  Ins 713  102 713  102 700  137 863  127 1,093  121 1,080  87 885  139 0.027
LBP (g/ml)
LPS 13.2  2.6 13.3  2.8 15.02  2.8 15.7  3.0 15.8  3.0 17.6  5.3 21.2  6.8 0.021 NS
LPS  Ins 11.5  2.0 11.1  1.7 12.0  2.2 12.5  2.1 12.5  1.8 14.8  2.8 20.2  3.8 0.019
Resistin (ng/ml)
LPS 7.72  0.9 7.78  0.7 9.57  0.8 17.69  1.3 23.83  2.2 24.74  2.4 11.69  1.5 0.001 NS
LPS  Ins 8.15  1.1 8.04  0.9 9.86  1.2 17.89  1.6 21.49  2.3 24.95  2.6 11.35  1.6 0.001
Data are means  SEM. *P  0.05 with one-way RMANOVA. †Two-way ANOVA. ‡P  0.05 with paired t test at 24 h compared with 1h .
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2A). Insulin infusion with LPS prevented
the LPS-induced increase of MIF during
the initial increase and suppressed it sig-
niﬁcantly during the secondary increase
(from 700  137 to 1,080  87 ng/ml at
6 h). The plasma concentration of TNF-
increased at 1 h, peaked between 1 and
2h( P  0.001, Table 1), and declined
thereafter, reaching near the baseline at
24 h. IL-6 increased at 1 h, peaked be-
tween 2 and4h( P  0.001) (Table 1),
anddeclinedtowardthebaselineby24h.
CRP concentration increased at6ha n d
was still elevated at 24 h (from 1.2  0.2
to 15.2  5.7 mg/l, P  0.001) (Table 1).
Insulin infusion did not alter the LPS-
inducedincreasesinTNF-,IL-6,orCRP
concentrations.
Plasma resistin, visfatin, and LBP
concentrations
Plasma visfatin concentrations increased
signiﬁcantly after LPS injection starting at
4h,peakedat6h(8737%abovebase-
line, from 11.4  1.2 to 19.2  2.4 ng/
ml, P  0.001) (Fig. 2B), and was
maintained at that level for 24 h. When
insulin was infused before LPS injection,
visfatin concentrations fell signiﬁcantly
from 11.9  1.5 to 7.7  1.1.0 ng/ml
(P  0.001) (Fig. 2B) at 4 h and were
signiﬁcantly different from that in the
controlgroup.LPSinjectionalsocauseda
signiﬁcant increase in resistin concentra-
tions, which started at 2 h after the injec-
tion, peaked at 6 h (223  25% above
baseline, from 8.1  1.1 to 24.7  4.7
ng/ml P  0.001) (Table 1) and contin-
ued to be higher than baseline at 24 h.
Plasma LBP concentrations increased
gradually after LPS injection and were
higher by 48  19% above the baseline at
2 4h( P  0.05) (Table 1). Insulin did not
cause any signiﬁcant change in the LPS-
induced increases in resistin or LBP
concentrations.
Plasma myoglobin and HMG-B1
concentrations
The plasma concentration of myoglobin
also increased signiﬁcantly from 22.3 
4.1 to 32.8  5.3 ng/ml at 4 h and to
39  5.8 ng/ml (P  0.05) at 24 h after
LPS injection (Fig. 3A). Insulin pre-
vented the increase in myoglobin con-
centrations. HMG-B1 concentrations in
plasma increased after LPS injection
Figure 1—Change in ROS generation by PMNL (A) and plasma con-
centrationsofTBARS(B)andNOM(C)aftera2ng/kgLPSinjection(at
0 h) in normal subjects with and without a 2-unit/h infusion of insulin
with5%dextrosefor6h.n	10and9each.DataaremeansSE.*and
**P  0.05 by RMANOVA from baseline; #P  0.05 by two-way
RMANOVA between the groups.
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3B), whereas insulin infusion had no ef-
fect on the LPS-induced increase in
HMG-B1concentrations.
CONCLUSIONS — Our data indi-
cate several novel observations on the
effects of LPS and insulin. They
demonstrate for the ﬁrst time the increase
in ROS generation, TBARS, NOM, resis-
tin, visfatin, myoglobin, and HMG-B1
concentrations in humans in vivo after an
LPS injection. They also show for the ﬁrst
time that insulin infusion reduces or to-
tally prevents the LPS-induced increases
inROSgenerationandtheconcentrations
of TBARS, NOM, MIF, visfatin, and myo-
globin. The relevance of each of these
novel effects is discussed below.
The LPS-induced increase in ROS
generation by PMNL and TBARS concen-
tration is evidence of marked oxidative
stress. Insulin suppressed the increase in
ROS generation signiﬁcantly while elimi-
nating the increase in TBARS altogether.
After LPS, NOM peaked at 2 h and re-
turned to the baseline by 4 h. The insulin
infusion eliminated the increase in the
NOM concentration. These actions of in-
sulin were independent of any change in
glucose concentrations.
Elevated plasma NOM concentra-
tions and inducible nitric oxide synthase
expression in the liver have previously
been shown to be suppressed by insulin
infusions in patients in ICUs (15). In this
study,theplasmaconcentrationsofNOM
in the highest quartile were associated
with seven times greater mortality than
those in the lowest quartile. Thus, the
NOM concentration could be an impor-
tant predictor of morbidity and mortality
in the ICU setting (16). Whether this ef-
fect on mortality is directly related to an
excess of nitric oxide generation or
whether the increased NOM levels are
merely markers of the intensity of sys-
temic inﬂammation is not clear. Either
way, the rapid induction of an increase in
NOM by LPS and its total prevention by
insulin are important and relevant
observations.
The biphasic increase in MIF after
LPS was reduced by insulin infusion. On
the other hand, insulin infusion did not
prevent LPS-induced increases in plasma
TNF-, IL-6, intercellular adhesion mol-
ecule-1, and MCP-1 concentrations. This
observation is in contrast to our previous
observation in patients with obesity and
type 2 diabetes in whom insulin sup-
pressed these mediators. CRP concentra-
Figure 2—Change in plasma concentrations of MIF (A) and visfatin (B) after a 2 ng/kg LPS
injection (at 0 h) in normal subjects with and without a 2-unit/h infusion of insulin with 5%
dextrosefor6h.n	10and9each.DataaremeansSE.*and**P0.05byRMANOVAfrom
baseline; #P  0.05 by two-way RMANOVA between the groups.
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injection at which time the infusion of in-
sulin ended. Clearly, further studies with
higher doses and for longer periods of in-
sulin infusion are required.
LPS also induced an increase in
plasma FFA concentrations within 1 h,
whichcontinuedfor24h,consistentwith
a potent lipolytic effect of LPS. This in-
crease was totally inhibited by insulin.
The suppressive effect of insulin FFA is
important because FFAs may induce oxi-
dative and inﬂammatory stress (17).
Our data also show for the ﬁrst time
that LPS injection in the human induced
an increase in plasma concentrations of
resistin and visfatin. Insulin infusion re-
sulted in the suppression of the increase
in visfatin but not resistin. The LPS-
induced increase in visfatin and the pre-
ventionofthisincreasewithinsulinareof
interestintermsnotonlyoftheacuteLPS-
induced inﬂammation but also of the
chronic inﬂammation in atherosclerotic
plaques because such plaques are known
to contain LPS- and TLR-4-expressing
macrophages (18). Such plaques also ex-
press visfatin, which may be secreted lo-
cally in response to the LPS-TLR-4
interaction(10).Itis,therefore,ofinterest
that insulin suppresses the LPS-induced
increase in visfatin and has previously
been shown to suppress TLR-4 expres-
sion (5). Resistin is also known to stimu-
late the secretion of proinﬂammatory
cytokines, and the evidence that its
concentration increases after LPS in the
human in vivo establishes it as a proin-
ﬂammatory mediator (19).
Plasma concentrations of LBP also
increased after LPS injection, demon-
strated for the ﬁrst time. The increase
started late, at 6 h, like that of CRP and
the previously described increase in
procalcitonin (20) and continued over-
night at 24 h. The increase in the con-
centration of LBP after LPS is important
because LBP facilitates the binding of
LPStoitsreceptor,TLR-4.AswithCRP,
the increase in LBP was not affected by
insulin, possibly because both in-
creased at 6 h and the insulin infusion
was stopped at that time.
It is of interest that although plasma
glucose concentrations did not alter sig-
niﬁcantly, insulin concentrations and
HOMA-IR increased signiﬁcantly 24 h af-
ter LPS injection in concert with the in-
duction of profound inﬂammation. This
result is consistent with the recent obser-
vation that the injection of LPS (3 ng/kg)
in normal subjects induced insulin resis-
tance as measured by frequently sampled
intravenous glucose tolerance and
HOMA-IR (21).
Our data also show for the ﬁrst time
that LPS induces an increase in HMG-B1
concentration in humans. Insulin did not
alter this increase. HMG-B1 is a nuclear
protein that binds to histones to promote
proinﬂammatory gene transcription. It
can be released from damaged, necrotic
tissues. Circulating HMG-B1 acts like a
proinﬂammatory cytokine through its
binding to the receptor for advanced gly-
cation end products (22).
The increase in plasma myoglobin
concentrationsafterLPSanditsinhibition
byinsulinisimportantbecauseitsigniﬁes
damage to the skeletal muscle and possi-
bly the myocardium. Consistent with this
observation, we have previously shown a
reduction in the increase in myoglobin
concentrations in patients with myocar-
dial infarction treated with intravenous
insulin infusions. This ﬁnding is sugges-
tive of a cytoprotective effect of insulin.
The mechanisms underlying the ef-
fects of insulin observed in this report are
probablyrelatedtoseveralofourprevious
observations. Insulin suppresses the ex-
pressionofTLR-4,thereceptorforLPS,to
reduce the activity of the major proin-
ﬂammatory transcription factor, NFB
(3,5).Insulinhasalsobeenshowntosup-
press ROS generation and the expression
Figure 3—Change in plasma concentrations of myoglobin (A) and HMG-B1 (B) after a 2 ng/kg
LPS injection (at 0 h) in normal subjects with and without a 2-unit/h infusion of insulin with 5%
dextrose for 6 h. n 	 10 and 9 each. Data are presented as means  SE. * and **P  0.05 by
RMANOVA from baseline; #P  0.05 by two-way RMANOVA between the groups.
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Insulin has been shown previously to
suppress inducible nitric oxide synthase
expression and the plasma NOM concen-
tration (15).
Consistent with our observations are
those of Jeschke et al. (23), who demon-
strated that compared with control sub-
jects, patients with severe burns given
insulin had lower MIF and other proin-
ﬂammatory cytokines and CRP concen-
trations with a tendency toward higher
IL-10 concentrations. Insulin infusion
with maintenance of normoglycemia has
been shown to reduce mortality and mor-
bidity in patients in a surgical ICU (24)
and in patients in a medical ICU (25),
whose stay in the ICU is for longer than 3
days.
In summary, the injection of LPS in
thehumaninducesanimmediateincrease
in ROS generation by PMNLs and in
plasma concentrations of TBARS, NOM,
FFA, MIF, resistin, visfatin, LBP, and
myoglobin. The concomitant infusion of
insulin induces a signiﬁcant reduction in
ROS generation and the total prevention
of the increase in TBARS, NOM, and FFA
concentrations. These actions were asso-
ciated with a signiﬁcant reduction in the
magnitudeofincreaseinMIF,myoglobin,
and visfatin concentrations indepen-
dently of any change in plasma glucose
concentrations. On the other hand, insu-
lin was not able to prevent or reduce the
magnitude of increase in plasma concen-
trations of proinﬂammatory cytokines
like TNF-, IL-6, or MCP-1. Clearly, the
effect of more prolonged infusions and
higher doses of insulin needs to be
investigated.
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